2-Bromo-5-chloroanisole | CAS:174913-09-8

We serve 2-Bromo-5-chloroanisole CAS:174913-09-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-5-chloroanisole

Chemical Name:2-Bromo-5-chloroanisole
CAS.NO:174913-09-8
Synonyms:2-Bromo-5-chloroanisole
1-Bromo-4-chloro-2-methoxybenzene
Molecular Formula:C7H6BrClO
Molecular Weight:221.47900
 
Physical and Chemical Properties:
Density:1.564
Melting point:ºC
Boiling point:236.6ºC
Flash point:96.9ºC
Index of Refraction:1.556
 
Specification:
Appearance:White to yellow solid
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2-Bromo-5-chloroanisole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Bromo-4-chloro-2-methoxybenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Bromo-5-chloroanisole Use and application,2-Bromo-5-chloroanisole technical grade,usp/ep/jp grade.


Related News: When using the raw materials, as an API manufacturer we produce API in the large reactor in our plant.2,4-Dichloro-3-aminophenol hydrochloride manufacturer Commonly used generic drugs: the products whose patents have expired and the generic drugs of many companies have participated in the competition, and the market demand is large.2-(2-methylprop-2-enoxy)phenol supplier With the death toll surging past 300 and 14,300 cases confirmed, authorities across the country have activated the highest public health emergency response, stepping up screening of arrivals from Wuhan.tert-Butyl 4-aminophenethylcarbamate vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).We are pleased that he is doing well,” said BPHC Executive Director Rita Nieves. “Right now, we are not asking Boston residents to do anything differently.